Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that a paliperidone palmitate 3 month formulation
(PP3M) is as effective as the paliperidone palmitate 1 month formulation (PP1M) in the
treatment of patients with schizophrenia who have been stabilized on PP1M.